Abstract
Biopharmaceuticals have transformed the treatment landscape for autoimmune diseases by offering targeted and effective therapeutic options. These biologically-derived agents, including monoclonal antibodies, cytokine modulators, and fusion proteins, are designed to modulate immune responses with high specificity. This article reviews the development of biopharmaceuticals in autoimmune disease therapy, highlighting key breakthroughs, clinical applications, safety considerations, and future research directions. The integration of biopharmaceuticals into treatment regimens represents a significant advancement in personalized and precision medicine.
References
Ahmad, N. R. (2025). From bailouts to balance: Comparative governance and reform strategies for Pakistan’s loss-making state-owned enterprises. Journal of Public Administration and Governance, 3(1), 120-134. https://doi.org/10.59075/t8pba787
Ahmad, N. R. (2025). AI-enabled public governance in developing states: Service delivery gains, accountability risks, and a practical risk-based regulatory model. World Journal of Administration, 5(2), 58-72. https://doi.org/10.52152/wja5db40
Ahmad, N. R. (2025). Exploring the relationship between leadership styles and employee motivation in remote work environments.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.